TrialAmerican journal of hematology2019

A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.

Nicholas J Short et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.